Circulating Ghrelin Levels Are Suppressed by Meals and Octreotide Therapy in Children with Prader-Willi Syndrome
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Prader-Willi syndrome (PWS) is characterized by severe obesity, hyperphagia, hypogonadism, and GH deficiency. Unlike individuals with common obesity, who have low fasting-plasma ghrelin concentrations, those with PWS have high fasting-ghrelin concentrations that might contribute to their hyperphagia. Treatment with octreotide, a somatostatin agonist, decreases ghrelin concentrations in healthy and acromegalic adults and induces weight loss in children with hypothalamic obesity. This pilot study was performed to determine whether octreotide administration (5 microg/kg.d) for 5-7 d lowers ghrelin concentrations and affects body composition, resting energy expenditure, and GH markers in children with PWS. Octreotide treatment decreased mean fasting plasma ghrelin concentration by 67% (P < 0.05). Meal-related ghrelin suppression (-35%; P < 0.001) was still present after intervention but was blunted (-11%; P = 0.19). Body weight, body composition, leptin, insulin, resting energy expenditure, and GH parameters did not change. However, one subject's parent noted fewer tantrums over denial of food during octreotide intervention. In conclusion, short-term octreotide treatment markedly decreased fasting ghrelin concentrations in children with PWS but did not fully ablate the normal meal-related suppression of ghrelin. Further investigation is warranted to determine whether long-term octreotide treatment causes sustained ghrelin suppression, changes eating behavior, and induces weight loss in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 2×
“T ENTERIC PEPTIDE ghrelin is an endogenous ligand for the GH secretagogue receptor (1) and is also a potent orexigenic in humans and other animals (2–5).”
BackgroundGhrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949
A role for ghrelin in the central regulation of feeding
Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001) · Nature · doi:10.1038/35051587 · Cited by 3,443
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494
The Novel Hypothalamic Peptide Ghrelin Stimulates Food Intake and Growth Hormone Secretion
Wren, A. M., Small, C. J., Ward, H. L., Murphy, K. G., Dakin, C. L., Taheri, S., Kennedy, A. R., Roberts, G. H., Morgan, D. G. A., Ghatei, M. A., et al. (2000) · Endocrinology · doi:10.1210/endo.141.11.7873 · Cited by 1,593
Genome Organization, Function, and Imprinting in Prader-Willi and Angelman Syndromes
Nicholls, R. D., & Knepper, J. L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.153 · Cited by 625 · cited 1×
“Prader-Willi syndrome (PWS) is the most common form of human syndromic obesity, resulting from a disruption of several imprinted genes on chromosome 15 (16).”
Background
Cited by
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
Cassidy, S. B., Schwartz, S., Miller, J. L., & Driscoll, D. J. (2012) · Genetics in Medicine · doi:10.1038/gim.0b013e31822bead0 · Cited by 1,452
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,282
Ghrelin and the short- and long-term regulation of appetite and body weight
Cummings, D. E. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.05.022 · Cited by 620
Self-citationGhrelin?a hormone with multiple functions
KORBONITS, M. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.03.002 · Cited by 595
10.1016/b978-1-4160-2911-3.50026-1
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/b978-1-4160-2911-3.50026-1 · Cited by 554
Prader-Willi syndrome: advances in genetics, pathophysiology and treatment
Goldstone, A. P. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2003.11.003 · Cited by 393
Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis
Elmquist, J. K., Coppari, R., Balthasar, N., Ichinose, M., & Lowell, B. B. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20786 · Cited by 390
Deal, C. L., Tony, M., Höybye, C., Allen, D. B., Tauber, M., Christiansen, J. S., & Participants, T. 2. G. H. I. P.-W. S. C. C. G. W. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3888 · Cited by 379
New targets to treat obesity and the metabolic syndrome
Martin, K. A., Mani, M. V., & Mani, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.093 · Cited by 121
Ghrelin’s Role as a Major Regulator of Appetite and Its Other Functions in Neuroendocrinology
Lim, C. T., Kola, B., Korbonits, M., & Grossman, A. B. (2010) · Progress in Brain Research · doi:10.1016/s0079-6123(10)82008-4 · Cited by 34
Metadata
- Authors
- Haqq, A. M., Stadler, D. D., Rosenfeld, R. G., Pratt, K. L., Weigle, D. S., Frayo, R. S., LaFranchi, S. H., Cummings, D. E., & Purnell, J. Q.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-08
- Volume
- 88
- Issue
- 8
- Pages
- 3573-3576
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2006689363
- Cited by
- 109
- References
- 6
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.